expected weight loss on semaglutide Program Seattle & Tacoma Tirzepatide causes more weight loss

Preclinical data show that GLP-1and by extension GLP-1R agonistscan modulate macrophage polarization: in vitro treatment of macrophages with GLP-1 reduced M1-specific markers (e.g., Inducible Nitric Oxide Synthase (iNOS), TNF-, IL-6) and increased M2-associated markers (e.g., IL-10, CD163, CD204) via signaling pathways involving increased signal transducer and activator of transcription 3 (STAT3) activation, thereby promoting an anti-inflammatory M2 phenotype [51]

If you're struggling with

Patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks Patients on semaglutide lost an average of 13.7% of their body weight over the same period 47% more tirzepatide patients achieved 25% or greater body weight loss compared to semaglutide Tirzepatide also produced greater reductions in waist circumference across all dose comparisons A 2024 meta-analysis published in JAMA Internal Medicine analyzing real-world data from over 140,000 patients confirmed the same pattern: tirzepatide produced an average of 4.23 kg more weight loss than semaglutide across all doses and durations studied

More clinical trials are needed to confirm their efficacy in cessation

Post-injection : Apply gentle pressure if needed, but do not massage